AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.56
+2.58%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | 1.3M | — |
| Gross Profit | — | — | — | (1.3M) | — |
| Operating Expenses | |||||
| R&D Expense | 102.8M | 90.3M | 73.3M | 63.9M | 42.2M |
| SG&A Expense | 35.3M | 22.5M | 22.8M | 19.8M | 18.1M |
| General & Admin Expense | 35.3M | 22.5M | 22.8M | 19.8M | 18.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 138.1M | 112.8M | 96.1M | 83.7M | 60.3M |
| Cost and Expenses | 138.1M | 112.8M | 96.1M | 85.0M | 60.3M |
| Operating Income (EBIT) | (138.1M) | (112.8M) | (96.1M) | (85.0M) | (60.3M) |
| Non-Operating | |||||
| Interest Income | 7.0M | 6.6M | 9.4M | 8.6M | 1.9M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.0M | 6.6M | 9.4M | 8.6M | 1.9M |
| Other Non-Op Income/Expense | 7.1M | 6.7M | 9.3M | 8.7M | 1.5M |
| Non-Operating Income (excl Interest) | (4.7M) | (6.7M) | (9.3M) | (8.7M) | (1.5M) |
| EBT (Pre-Tax Income) | (130.9M) | (106.1M) | (86.8M) | (76.3M) | (58.8M) |
| Income Tax Expense | 81.0K | 108.0K | 112.0K | 137.0K | — |
| Bottom Line | |||||
| Net Income | (131.0M) | (106.2M) | (86.9M) | (76.4M) | (58.8M) |
| Earnings from Cont. Ops | (131.0M) | (106.2M) | (86.9M) | (76.4M) | (58.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (131.0M) | (106.2M) | (86.9M) | (76.4M) | (58.8M) |
| Per Share | |||||
| Basic EPS | ($1.78) | ($1.76) | ($1.75) | ($1.93) | ($1.96) |
| Diluted EPS | ($1.78) | ($1.76) | ($1.75) | ($1.93) | ($1.96) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 94.9M | 60.3M | 49.7M | 39.6M | 29.9M |
| Diluted Shares Outstanding | 94.9M | 60.3M | 49.7M | 39.6M | 29.9M |
| Profitability Metrics | |||||
| EBITDA | (131.6M) | (105.0M) | (85.6M) | (75.0M) | (57.6M) |
| D&A | 1.7M | 1.1M | 1.2M | 1.3M | 1.2M |
| EBIT | (133.4M) | (106.1M) | (86.8M) | (76.3M) | (58.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026